EANS-News: november Aktiengesellschaft
PROGEN Biotechnik GmbH - Significant
Increase of 3rd Quarter Operating Results
Cologne (euro adhoc) -
PROGEN Biotechnik GmbH reports significant sales increase Significant increase in operating profit Significantly improved margins Consolidated results nearly break-even
Corporate news transmitted by euro adhoc. The issuer/originator is solely responsible for the content of this announcement.
Annual Reports/Financial Figures/Balance Sheet/quarterly report/9-month report
Subtitle: PROGEN Biotechnik GmbH reports significant sales increase Significant increase in operating profit Significantly improved margins Consolidated results nearly break-even
november AG, Cologne, listed in the Prime Standard of the German Stock Exchange (WKN A0Z24E) is publishing figures for the first nine month of 2010 on November 12, 2010. Especially promising are the HRB (DVFA/SG) results of PROGEN Biotechnik GmbH, the major holding of the november AG. Measures taken and increased sales activities of PROGEN show considerably positive effects in the 3rd quarter of 2010.
July through September sales revenues and other operating income show an increase of TEUR 170 to TEUR 1.221, i.e. approx 16.2% as compared to the same period last year (TEUR 1.051). At the same time, PROGEN´s 3rd quarter operating profit of TEUR 187 are significantly higher as compared to the same period last year (TEUR 102), i.e. an increase of approx. 83.3%. This disproportional profit increase is a result of improved margins because of higher sales and only slightly increased purchase prices and nearly constant operating costs.
This positive trend of PROGEN is also confirmed by direct comparison of the 2nd and 3rd quarter of 2010. The HGB turnover and other operating income increased from TEUR 1.102 to TEUR 1.221 and operating profits from TEUR -11 to TEUR 187. PROGEN Biotechnik expects this positive trend to continue also in Q4.
Overall, these developments also have significantly positive effects on the consolidated results: 3rd quarter figures are nearly break-even. november AG is now on a solid course for profitable growth. For a detailed Q3 report 2010, please refer to: www.november.de/berichte
end of announcement euro adhoc
Further inquiry note:
Dr. Dirk Zurek
Vorstand
Tel.: +49 (0) 221 82200 520 10
E-Mail: ir@november.de
Branche: Biotechnology
ISIN: DE000A0Z24E9
WKN: A0Z24E
Index: CDAX, Prime All Share, Technology All Share
Börsen: Frankfurt / regulated dealing/prime standard
Berlin / free trade
Stuttgart / free trade
Düsseldorf / free trade
Hannover / free trade
München / free trade